Clinical trials: Risk Behaviors
Risky Sexual Behavior, Emotion Regulation
An Interactive Education Program to Reduce High Risk Behavior in Adolescents Ph II (iTRAC HERO)
Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will create and test iTRAC-HERO to teach emotion regulation skills in the context of sexual health education.
- Conditions
- Risky Sexual Behavior, Emotion Regulation, Adolescent Behavior
- Trial name
- iTRAC-HERO (NCT06894277)
- Testing
- iTRAC-HERO
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Klein Buendel, Inc.
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Risk Behavior, Cognitive Decline
Multidomain Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help middle-aged to older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors…
- Trial name
- NCT05141578
- Testing
- Luci Coach Assisted Intervention
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- LuciLab
Epilepsy
WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1.
- Trial name
- NCT01607333
- Testing
- Lamotrigine use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, Nonadherence, Patient
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
This study evaluates the ability of digital medicines, Proteus Discover, to promote adherence and thus achieving a cure for hepatitis C in patients at high risk for not adhering to their hepatitis therapy.
- Trial name
- DASH (NCT03164902)
- Testing
- Digital Medicine
- Where
- 16 sites in United States
- Volunteers
- 253 people
- Sponsor
- Proteus Digital Health, Inc.
Smoking
Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study
The main goal of this exploratory study is to evaluate the pharmacokinetic profile of nicotine for the candidate modified risk tobacco product THS 2.1 and for conventional cigarettes (CC).
- Trial name
- NCT01780688
- Testing
- Conventional cigarettes (CC), THS 2.1
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Lifestyle Risk Reduction
Analysis of Correlation Between Skin Carotenoid Level and Basic Indicators of Health Status Related to Lifestyle in Vietnamese: An Observational Study
To clarify the relationship between vegetable intake and lifestyle-related disease in Vietnam, we measure skin carotenoid levels and basic indicators of health status related to lifestyle and analyze the correlation between them.
- Trial name
- NCT06271070
- Testing
- Non-intervention
- Where
- Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- KAGOME CO., LTD.
Pathological Gambling
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
- Trial name
- NCT01215357
- Testing
- Ecopipam
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Emalex Biosciences Inc.
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
The overall goal of the study is to evaluate the pharmacokinetic (PK) profile (rate and the amount of nicotine absorbed) following a single use of the THS 2.2, a candidate Modified Risk Tobacco Product, compared to the PK…
- Trial name
- NCT01959607
- Testing
- THS 2.2, CC, NRT Gum
- Where
- Japan
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Gambling Addiction
Validation of Kaihani Score for Gambling Addiction
The Kaihani Score is a blood based means of assessing molecules believed to be associated with gambling addiction. The current clinical trial will assess the Kaihani Score in 3 groups: Group 1: 10 patients with no personal or…
- Trial name
- NCT04648007
- Testing
- Kaihani Score
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Therapeutic Solutions International
Adolescent Behavior, Sleep Disturbance
Personalized Approach To Habits - Sleep
Two arm study, intervention and control, to explore the impact of an app to help high risk teens with asthma improve their sleep
- Conditions
- Adolescent Behavior, Sleep Disturbance, Asthma in Children, Knowledge, Attitudes, Practice
- Trial name
- PATH-S (NCT07029919)
- Testing
- PATH-S app
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- KDH Research & Communication
Smoking
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
The objective of the ZRHR-ERS-09-EXT-US study is to further assess the effect of the Tobacco Heating System 2.2 (THS 2.2), a candidate Modified Risk Tobacco Product, compared to conventional cigarettes (CC) on the components of…
- Trial name
- NCT02649556
- Testing
- THS 2.2, CC
- Where
- 19 sites in United States
- Volunteers
- 672 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Risk Behavior, Cognitive Decline
Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors associated with…
- Trial name
- NCT04616794
- Testing
- Cognitive Engagement Group, Physical Activity Group, Diet Group
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- LuciLab
Addiction, Behavioral Addiction
Mobile Health for Problematic Behaviors and Substance Use
The aim of the study is to evaluate the effectiveness of long-term and short-term app-based self-guided psychological interventions to reduce craving and lapse risk in problematic behaviors (compulsive sex, pornography…
- Conditions
- Addiction, Behavioral Addiction, Nicotine Addiction, Nicotine Dependence
- Trial name
- NCT05434429
- Testing
- mobile application
- Where
- Poland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PredictWatch
Addiction, Addiction, Alcohol
The Efficacy of a Mobile Application in Reducing Craving and Lapse Risk in Alcohol and Stimulants Problematic Use
The aim of the study is to evaluate the effectiveness of long-term and short-term app-based self-guided psychological interventions to reduce craving and lapse risk in users with substance use disorder or problematic substance…
- Conditions
- Addiction, Addiction, Alcohol, Addiction, Substance
- Trial name
- NCT05434416
- Testing
- mobile app
- Where
- Poland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PredictWatch
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative…
- Trial name
- Caprelsa104 (NCT01945762)
- Testing
- Vandetanib 300 mg
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company
Depressive Disorder, Major, Suicidal
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in…
- Trial name
- NCT04669665
- Testing
- SLS-002, Standard of care, Intranasal device
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- Seelos Therapeutics, Inc.
Smoking
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
The aim of the study is to demonstrate clinical, biological and functional health changes in smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2 (THS 2.2) as compared to smokers continuing…
- Trial name
- NCT02396381
- Testing
- THS 2.2, CC
- Where
- 19 sites in United States
- Volunteers
- 1,039 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Pathological Gambling
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
- Trial name
- NCT00132119
- Testing
- nalmefene HCl
- Volunteers
- 233 people
- Sponsor
- Somaxon Pharmaceuticals